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incidence and epidemiology
An estimated 1.6 million new lung cancers are diagnosed
worldwide each year. The highest incidence rates in males are
observed in Central/Eastern and Southern Europe (57 and 49
per 100 000, respectively), whereas in women the highest
rates are found in Northern Europe (36 per 100 000) [1].
Five-year survival rates of lung cancer patients have only
slightly improved during the past decade but remain low at
10% [2].
Small-cell lung cancer (SCLC) originates from
neuroendocrine-cell precursors and is characterised by its
rapid growth, its high response rates to both chemotherapy
and radiotherapy and development of treatment resistance in
patients with metastatic disease. In the Western world, the
proportion of patients with SCLC has decreased to 13% [3].
Virtually all patients have a history of tobacco use. Therefore,
smoking habits are closely linked to incidence, which varies
across different populations. In addition, the new description
of large-cell neuroendocrine tumours in the 1990s, which
may have been summarised previously as SCLC, possibly has
contributed to the decline. Smoking cessation not only
reduces the risk of developing SCLC but also has been shown
to decrease the risk of death of patients with localised SCLC
by almost 50% [4]. Only one-third of the patients are
diagnosed with localised disease, where cure is the treatment
goal. Due to the aggressive natural course, screening by
radiological imaging is unlikely to lead to a reduction of
mortality, and smoking prevention will undoubtedly remain
the primary and most important intervention to further
decrease mortality [5].
diagnosis and pathology/molecular
biology
Pathological diagnosis should be made according to the
World Health Organisation (WHO) classiﬁcation using
morphology (uniform round to spindled-shaped small cells,
sparse cytoplasm, high mitotic index, necrotic areas).
Immunohistochemistry to conﬁrm the diagnosis of SCLC
(synaptophysin, chromogranin A, CD56, thyroid
transcription factor 1 and MIB-1) is not mandatory, but
should be used in case of any doubt (e.g. in case of
pronounced crush artefacts). Due to its frequent central
localisation within the chest, biopsies may best be obtained by
bronchoscopy. Other methods include mediastinoscopy,
endobronchial ultrasound (EBUS), endoscopic ultrasound,
transthoracic needle aspiration or even thoracoscopy if
necessary. A biopsy from a metastatic lesion may be the
preferred option if the location of the metastasis is easily and
safely accessible to biopsy, as this will also pathologically stage
the patient (e.g. liver, skin).
staging and risk assessment
The prognosis of SCLC strongly depends on the tumour stage.
The new tumour-node-metastasis (TNM) version 7 staging
system according to the Union for International Cancer Control
(UICC) as adopted for non-small-cell lung cancer should also
be used for SCLC [I, A] [6,7] (See Tables 1 and 2). This
classiﬁcation should replace the former 1989 International
Association for the Study of Lung Cancer (IASLC) staging
system, which deﬁned limited stage as tumour being conﬁned to
one hemithorax with regional lymph node metastasis including
both ipsilateral and contralateral hilar, supraclavicular and
mediastinal nodes, as well as ipsilateral pleural effusion. The
current TNM staging system is based on 8088 SCLC patients
and provides better prognostic information and more precise
nodal staging, which is required for conformal radiation
techniques and intensity-modulated radiation therapy. The
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former term limited stage would now include T1-4, N0-3 M0
tumours, whereas metastatic tumours encompass former
extensive stage patients. In addition, T1 or T2 N0 or N1 M0
tumours (previously described as ‘very limited stage’) were
identiﬁed as a group with a more favourable outcome compared
with patients with N2 or N3 disease.
Initial assessment should encompass medical history
including smoking history, physical examination, complete
blood count including differential count, liver enzymes, sodium,
potassium, calcium, glucose, lactate dehydrogenase levels and
renal function tests, and in the case of localised disease, lung
function tests. An initial computed tomography (CT) scan with
contrast of the chest and abdomen is recommended. If the
metastatic stage is not obvious on the CT scan or clinical
ﬁndings suggest bone or brain involvement, further imaging
with bone scintigraphy and CT or magnetic resonance imaging
(MRI) of the brain are recommended. In case of abnormal
blood count or signs of blood–bone marrow barrier rupture
(e.g. peripheral blood erythroblasts), a bone marrow aspiration
and biopsy may be indicated, particularly in patients with
otherwise absent metastases [V, C]. Alternatively to CT and
bone scintigraphy, a 2-ﬂuor-2-deoxy-D-glucose positron-
emission-tomography (FDG-PET) CT scan can be carried out.
A recent review has suggested that with PET-CT 9% of the
patients are up- and 4% downstaged [8]; however, individual
studies in this analysis were non-randomised and were either
retrospective or small and frequently lacked histological
conﬁrmation. Thus, PET-CT ﬁndings which could impact
treatment decisions should be pathologically conﬁrmed [III, C].
In patients with a solitary metastasis, its pathological
conﬁrmation should not delay treatment start. In this case, the
solitary metastatic lesion’s size should be re-evaluated after two
cycles, allowing further judgement as to whether it is a true
metastatic site [V, C]. Alternatively, an initial second
radiological method (e.g. MRI if solitary small liver or bone
lesion) is recommended [V, C]. If a pleural or pericardial
effusion is the only site of M1, no malignant cells are identiﬁed
in the pleural ﬂuid and a plausible explanation other than
tumour involvement is clinically suspected, treatment should be
according to an M0 status [V, B].
management of localised disease
(t1-4, n0-3 m0)
In localised disease, median survival and 2-year survival rates
have been reported to be 15–20 months and 20%–40%
respectively [9]. Importantly, the proportion of patients who
survive for 5 years has been reported to be 20%–25% [10].
Approximately 5% of patients with SCLC present as T1, 2 N0,
1 M0 tumours (Figure 1). These patients have more favourable
outcomes with 5-year survival rates in the order of 50% [11, 12].
Most series report on patients having been treated with surgery
for a coin lesion without pathological diagnosis. A surgical
approach in this group of patients is justiﬁed after ruling out
mediastinal lymph node involvement (i.e. negative lymph nodes
on CT scan, PET-CT scan or EBUS and/or mediastinoscopy if
enlarged) [V, C]. Postoperatively, four cycles of adjuvant
chemotherapy should be administered [III, C]. In the case of
unforeseen N2 or N1 or in patients who have not undergone
systematic nodal dissection, postoperative radiotherapy should
be considered [V, C]. There is no role for surgery after induction
chemotherapy in N2 disease [II, B]. In the absence of
randomised trials, due to frequent early dissemination and
because total gross tumour volume has shown to be an
Table 2. Tumour stage grouping.
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a,b N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
T1a,b N1 M0
T2a N1 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1a,b, T2a,b N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1
Lababede O, Meziane M, Rice T. Seventh Edition of the Cancer Staging
Manual and Stage Grouping of Lung Cancer. Chest 2011; 139: 183–189.
Reproduced with permission from the American College of Chest
Physicians.
Table 1. Tumour node metastasis classiﬁcation.
TX Positive cytology only
T1 ≤3 cm
T1a ≤2 cm
T1b >2 to 3 cm
T2 Main bronchus ≥2 cm from carina invades visceral pleura, partial
atelectasis
T2a >3–5 cm
T2b >5–7 cm
T3 >7 cm; chest wall, diaphragm, pericardium, mediastinal pleura,
main bronchus <2 cm from carina, total atelectasis, separate
nodule(s) in the same lobe
T4 Mediastinum, heart, great vessels, carina, trachea, esophagus,
vertebra; separate tumour nodule(s) in a different ipsilateral lobe
N1 Ipsilateral peribronchial, ipsilateral hilar
N2 Subcarinal, ipsilateral mediastinal
N3 Contralateral mediastinal or hilar, scalene or supraclavicular
M1 Distant metastasis
M1a Separate tumour nodule(s) in a contralateral lobe; pleural nodules
or malignant pleural, or pericardial effusion
M1b Distant metastasis
Lababede O, Meziane M, Rice T. Seventh Edition of the Cancer Staging
Manual and Stage Grouping of Lung Cancer. Chest 2011; 139: 183–189.
Reproduced with permission from the American College of Chest
Physicians.
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independent prognostic factor leading to improved outcomes
irrespective of the local treatment modality, patients with T1, 2
N0, 1 M0 may alternatively be treated with combined
concurrent chemoradiotherapy [III, C] [13]. This treatment is
recommended as the ﬁrst option in patients who are at
increased risk for perioperative complications (e.g. signiﬁcant
concomitant medical illnesses) [II, C]. All patients with T1, 2
N0, 1 M0 should be considered for prophylactic cranial
irradiation (PCI) if they have responded to initial treatment
using the same dose and fractionation as for patients with stage
III SCLC.
All other patients with T1-4, N0-3 M0 tumours who are in a
good performance status (PS) should be treated with concurrent
chemotherapy and thoracic radiotherapy [I, A]. Several
radiotherapy schedules have been studied. One phase III trial of
471 patients reported a superior 5-year overall survival (OS)
with twice-daily radiotherapy (1.5 Gy twice-daily, 30 fractions)
compared with once-daily (1.8 Gy, 25 fractions) of 26% versus
16% (P = 0.04) [10]. The inconvenience of the twice-daily
administration and the signiﬁcantly increased rate of transient
grade 3 oesophagitis were, however, the main reasons why this
regimen was not widely adopted. This current accelerated
standard schedule is being compared with 70 Gy in daily
fractions as an experimental arm in ongoing North American
and European phase III trials in patients in which the lung dose
can be kept within safe limits. Outside of a clinical trial, a twice-
daily 1.5 Gy in 30-fraction regimen should be considered in ﬁt
patients who are willing to accept temporarily increased toxicity
[I, B]. The chemotherapy schedule consists of four cycles of
cisplatin–etoposide or 4–6 cycles if a once-daily radiotherapy
schedule is used [I, B].
The optimal timing of the concurrent radiotherapy has been
studied extensively. Seven older trials assessing the timing of
thoracic radiotherapy were analysed in two meta-analyses, with
the conclusion that thoracic radiotherapy should be initiated as
early as possible beginning with the ﬁrst or second cycle when
cisplatin-based chemotherapy was used [14, 15]. In addition, an
analysis of four of these studies which reported 5-year survival
rates and used two concurrent arms with cisplatin–etoposide
treatment found improved 5-year survival rates if the time
between the ﬁrst day of chemotherapy and the last day of
radiotherapy was <30 days [hazard ratio (HR): 0.62, 95%
conﬁdence interval (CI) 0.49–0.80, P = 0.0003] [16]. An update
of an American trial reached the same conclusion [17]. On the
other hand, a recent randomised trial did not show any survival
difference when radiotherapy was administered with the third as
opposed to the ﬁrst cycle with less toxicity in the late arm in an
Asian population [18]. Starting chest radiotherapy within 30
days after the beginning of chemotherapy is preferred [II, B].
When the general condition of the patient does not allow for the
immediate administration of concurrent treatment or lung
constraints preclude the target radiotherapy dose, chest
irradiation may be postponed until the start of the third cycle of
chemotherapy [II, B].
The optimal target volume remains to be deﬁned. Omission
of elective node irradiation based on CT scans should be used
with caution as this strategy may result in nodal failures [III, C].
Whether selective node irradiation based on pre-treatment
PET-CT scans can replace elective node irradiation has been
addressed in two small studies [19, 20]. Both studies, one
prospective and the other one retrospective, have shown
promisingly low nodal recurrence rates. This strategy, however,
needs further prospective evaluation although it has been
adopted already in some national guidelines [III, D]. Elective
nodal volumes are not well-deﬁned but may include the
involved lymph node regions and one adjacent region and
supraclavicular regions depending on the location of the
primary tumour and the N2 or N3 nodes.
RECIST criteria are not well-suited to determine tumour
response after radiotherapy. Patients in a reasonably good PS
without progression should be offered PCI. The recommended
dose is 25 Gy in 10 daily fractions [I, A]. Although PCI
increases long-term survival, patients >65 years and/or with
important vascular disease have a slightly elevated risk (HR
1.04) of developing neurocognitive side-effects [21, 22].
management of metastatic disease
ﬁrst-line treatment
Treatment of stage IV SCLC is palliative, and combination
chemotherapy has been the main treatment option for more
Figure 1. Small-cell lung cancer (SCLC) treatment algorithm.
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than three decades. Despite response rates (RRs) close to 70%,
outcomes remain poor with a median progression-free
survival (PFS) of only 5.5 months and a median OS of <10
months [22, 23].
A meta-analysis of 19 randomised trials with a total of 4054
patients demonstrated prolonged OS of patients receiving a
cisplatin-containing regimen compared with older
chemotherapy combinations [25]. Another meta-analysis of 36
trials reported an OS beneﬁt in favour of etoposide alone or in
combination with cisplatin compared with regimens that did
not contain one of the two drugs [26]. These results led to the
adoption of etoposide–cisplatin as a standard treatment
regimen. A recent individual patient data meta-analysis
including four randomised clinical trials comparing cisplatin
versus carboplatin-based combination chemotherapy
demonstrated no difference in efﬁcacy outcomes including RR,
PFS and OS [24]. In the carboplatin group, increased
haematological toxicity rates were observed, whereas higher
renal and neurotoxicity was seen with cisplatin. According to
these results, cisplatin can be substituted by carboplatin in
patients with metastatic SCLC [I, B]. Due to the limited number
of only 663 patients included in this analysis, there was limited
statistical power to draw conclusions in important subgroups
such as patients with localised disease and young patients. In
these subgroups, etoposide–cisplatin is recommended [II, B].
Studies with 3-drug regimens and the administration of
increased dose intensity regimens, using increased dose or non-
cross-resistant regimens, have not consistently reported
improvement in OS. In addition, they have frequently been
associated with signiﬁcant toxicity in this usually co-morbid
patient population [27]. Such regimens are not recommended as
ﬁrst-line treatment [II, C].
A recent literature-based meta-analysis of seven randomised
studies showed an improved OS, but not PFS with irinotecan–
platinum compared with etoposide–platinum. Irinotecan led to
more gastrointestinal toxic effects, while more haematological
toxic effects were observed with etoposide [28]. The results,
however, were primarily driven by Asian studies, and
pharmacogenomic differences between Asian and Western
populations possibly contributing to these differential outcomes
have previously been described [29]. No chemotherapy doublet
has yet been shown to be superior to i.v. etoposide–platinum in
a Western population. Randomised phase III trials which
compared irinotecan–cisplatin, gemcitabine–carboplatin (in
poor prognostic patients only) or i.v. or oral topotecan–cisplatin
to etoposide–platinum have demonstrated non-inferiority for
survival [30–33]. These regimens are recommended as
alternative treatment options in the case of contraindications to
etoposide [II, C].
Continuation of chemotherapy beyond 4–6 cycles has been
assessed in at least 14 randomised, controlled trials. Although a
signiﬁcant OS beneﬁt was reported in a literature-based review
including 11 trials (HR 0.89, 95% CI: 0.81–0.92; P = 0.02), the
beneﬁt was small and high heterogeneity among the included
trials was observed [34]. Similarly, a previous meta-analysis
found a small OS beneﬁt of 4% at 2 years with maintenance
therapy [35]. However, the majority of the randomised,
controlled trials did not show any signiﬁcant OS beneﬁt, and a
properly designed large clinical trial to address this question is
lacking. In addition, there is a considerable risk of increased
toxicity with prolonged platinum-based chemotherapy.
Continuing chemotherapy beyond 4–6 cycles of ﬁrst-line
treatment is not recommended [II, B].
PCI signiﬁcantly decreases the risk of symptomatic brain
metastases (from 40.4% to 14.6% at 1 year) and increases OS
(HR 0.68; 95% CI, 0.52–0.88) [36]. Of note, in this trial initial
pre-treatment brain imaging was not required. PCI is associated
with adverse effects such as fatigue and hair loss, and health-
related quality of life may be negatively affected as well [37].
Patients with any response to ﬁrst-line treatment and who have
a reasonably good PS should be evaluated for PCI [II, B]. The
PCI dose may be 25 Gy in 10 daily fractions or 20 Gy in 5
fractions.
Due to the often centrally located primary tumours,
symptoms such as dyspnoea, infections due to atelectasis, chest
pain or superior vena cava syndrome are frequent and make the
incorporation of thoracic radiotherapy into the initial treatment
algorithm an appealing concept. A four-arm randomised phase
III trial has demonstrated a survival beneﬁt of concurrent
thoracic radiotherapy in patients whose primary tumours have
responded after three cycles of cisplatin–etoposide and whose
metastatic sites were in complete remission (OS: 17 versus 11
months, P = 0.041) [38]. This single centre trial was however
small (54 patients per arm), and the concurrent
chemoradiotherapy treatment used does not correspond to the
current standard approach. The routine use of thoracic
irradiation in patients with metastatic SCLC is not
recommended and the results of the Dutch phase III trial
(CREST study) testing this concept should be awaited [II, C].
second-line treatment
RRs to second-line treatment depend on the treatment-free
interval and are usually in the order of 10% in resistant disease
(i.e. progression-free interval <3 months) and 20% in sensitive
disease (i.e. interval >3 months). In refractory patients (i.e.
patients not responding or progressing during chemotherapy)
and resistant patients with early relapse (<6 weeks), outcomes
are poor and the clinical beneﬁt of further systemic therapy is
uncertain. For these patients, participation in a clinical trial or
best supportive care is recommended [II, C]. Oral topotecan led
to better symptom control including slower time to quality of
life deterioration and improved survival compared with best
supportive care in a study in which half of the patients had
resistant disease [39]. Prior to topotecan development,
anthracycline-based regimes have been commonly used,
including cyclophosphamide, doxorubicin and vincristine
(CAV). In 1999, a trial of i.v. topotecan and CAV demonstrated
equal efﬁcacy, with similar RRs, time-to-progression, and OS,
and better tolerance when compared with CAV [40]. Oral and
i.v. topotecan have shown to be equally effective [41], but with
differing toxicity proﬁles. Either oral or i.v. topotecan are
recommended for patients having resistant or sensitive relapse
with CAV being an alternative option [II, B]. Only patients with
sensitive disease derive beneﬁt from rechallenge with ﬁrst-line
therapy (usually platinum–etoposide) [V, C].
A recent randomised, phase III trial failed to show a survival
beneﬁt of amrubicin versus topotecan, despite a higher RR and
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Table 3. Summary of recommendations.
Diagnosis • Pathological diagnosis should be made according to the World Health Organisation (WHO) classiﬁcation
• Biopsies are best obtained by bronchoscopy. A biopsy from a metastatic lesion is preferred if the location of the
metastasis can be easily and safely accessed to biopsy (e.g. liver, skin)
•No predictive molecular marker for treatment selection is currently available
Staging and risk assessment • Initial assessment should include smoking history, physical examination, complete blood count, liver enzymes, sodium,
potassium, calcium, glucose, lactate dehydrogenase levels and lung (if localised disease) and renal function tests
•A computed tomography (CT) scan with contrast of the chest and abdomen is recommended
• In localised disease or if symptoms or clinical ﬁndings suggest involvement, additional bone scintigraphy and CT or MRI
of the brain are recommended
• 2-ﬂuor-2-desoxy-D-glucose positron-emission-tomography (FDG-PET CT) scan is optional in localised disease. PET
ﬁndings, which modify treatment decisions, should be pathologically conﬁrmed [III, C]
•A bone marrow aspiration and biopsy should be carried out in the case of abnormal blood counts suggesting
involvement, particularly in localised disease [V, C]
•Version 7 of the TNM staging system according to the Union for International Cancer Control (UICC) should be used
(Tables 1 and 2) [I, A]
Treatment strategy • Figure 1 summarises the treatment algorithm of patients with SCLC
• In localised disease, a bimodality treatment approach is curative and chemotherapy plus radiotherapy result in 5-year
survival rates of 20%–25%
• Treatment of stage IV SCLC is palliative and various combination chemotherapy regimens demonstrate similarly high
response rates (RRs) of 60%–70%. Due to frequent rapid relapse and limited activity of second-line treatment, overall
survival (OS) remains poor (<10 months)
•All SCLC patients responding to ﬁrst-line treatment should be evaluated for prophylactic cranial irradiation (PCI)
Treatment of localised
disease
•A small subset of patients who present with T1, 2 N0, 1 M0 tumours have a more favourable outcome and 5-year
survival rates of 50% have been reported with surgery. These patients should receive four cycles of adjuvant chemotherapy
[III, C] and postoperative thoracic radiotherapy if staged pN1 or pN2 [V, C]
•All other patients with T1-4, N0-3 M0 tumours who are in a good performance status (PS) should be treated with
concurrent chemotherapy and thoracic radiotherapy [I, A]
• The best OS rates in ﬁt patients were demonstrated with twice-daily 1.5 Gy in 30 fractions given concurrently with four
cycles of cisplatin and etoposide [I, B]
• Patients who are not ﬁt enough for twice-daily radiotherapy or are unwilling to accept increased toxic effects may be
treated with a once-daily radiotherapy schedule with 4–6 cycles of concurrent etoposide–cisplatin [I, B]
• In good PS patients, thoracic radiotherapy should be initiated with the ﬁrst or second cycle (i.e. within 30 days) of
chemotherapy [II, B]
•All patients with T1-4, N0-3 M0 disease without disease progression after treatment and a reasonably good PS should be
offered PCI [I, A]
First-line treatment of
metastatic disease
• 4–6 cycles of etoposide plus cisplatin or carboplatin are recommended [I, B]
• In young patients and patients with localised disease, etoposide–cisplatin is recommended [II, B]
• Irinotecan–cisplatin, gemcitabine–carboplatin (in poor prognostic patients only) and i.v. or oral topotecan–cisplatin are
alternative options if etoposide is contraindicated [II, C]
• Patients in a reasonably good PS with any response to ﬁrst-line treatment should be evaluated for PCI [II, B]
• The routine use of thoracic irradiation in patients with metastatic SCLC is not recommended [II, C]
Second-line treatment of
metastatic disease
• For refractory patients and resistant patients with early relapse (<6 weeks), participation in a clinical trial or best
supportive care is recommended [II, C]
•Oral or i.v. topotecan are recommended for patients having resistant or sensitive relapse with CAV being an alternative
option [II, B]
• Patients with sensitive relapse may derive beneﬁt from reintroduction of the ﬁrst-line regimen (usually platinum–
etoposide) [V, C]
Follow-up and long-term
implications
• The occurrence of second malignancies, particularly if smoking is continued, is of concern in survivours and smoking
cessation counselling is essential
• Two to three-monthly CT scans are recommended in patients with metastatic disease potentially qualifying for further
treatments [V, C]
• Six-monthly CT scans for 2 years with lengthening of intervals thereafter are recommended for patients with non-
metastatic disease who have received potentially curative treatment [V, C]
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improved quality of life with amrubicin [42]. The subgroup of
refractory patients derived a small survival beneﬁt from
amrubicin. Amrubicin is currently not available in Western
countries.
personalisedmedicine
In this disease setting, more research is needed to identify
molecular markers which could lead to advances in
personalised medicine.
follow-up and long-term implications
All patients with metastatic SCLC and approximately three-
quarters of patients with localised disease will progress. In
survivors, the occurrence of second malignancies, particularly if
smoking is continued, is of concern and smoking cessation
counselling is essential. The main goal of regular follow-up is to
detect recurrence early, while the patient is still in a good PS
[43]. The frequency of follow-up visits depends on the
availability of treatment options. Although there is no clinical
trial evaluating the beneﬁt of regular follow up, 2–3-monthly
CT scans are recommended in patients with metastatic disease
potentially qualifying for further treatments. Patients with
localised disease who have received potentially curative
treatment should undergo 3–6-monthly CT scans for two years
with lengthening of intervals thereafter. Due to the high risk of
secondary primary lung cancer, annual low-dose CT scans after
5 years might be considered [V, C]. Summary of
recommendations is provided in Table 3.
note
Levels of evidence and grades of recommendation have been
applied using the system shown in Table 4. Statements without
grading were considered justiﬁed standard clinical practice by
the experts and the ESMO faculty.
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